+351 211 369 829 INFO@OPHIOMICS.COM

Ophiomics wins the SME Instrument Phase I

Ophiomics was granted the SME Instrument Phase I grant to conduct a Feasibility study for its HepatoPredict genomic signature for Liver Cancer. Check here for the CORDIS page.  This grant will permit Ophiomics to build a business case for HepatoPredict.

Share the Post:

Related Posts

Ophiomics @ Arab Health 2023

🚀Off to #ArabHealth2023 with the #EUeic Overseas Trade Fairs ✈️Programme 2.0! Pay us a visit at the European Pavilion (Za’abeel Hall 6 – Booth Z6.C25).

Read More